STOCK TITAN
  1. Home
  2. Sec-filings
  3. OLMA
  4. [8-K] Olema Pharmaceuticals, Inc. Reports Material Event

Olema Pharmaceuticals (NASDAQ: OLMA) investors approve board slate, pay plan and Ernst & Young

Filing Impact
(Moderate)
Filing Sentiment
(Neutral)
Form Type
8-K

Rhea-AI Filing Summary

Olema Pharmaceuticals, Inc. reported the results of its annual stockholder meeting held on June 17, 2026. Stockholders elected four Class III directors—Sean Bohen, Scott Garland, Yi Larson, and Andrew Rappaport—to serve until the 2029 annual meeting and until their successors are elected and qualified.

Stockholders also approved, on an advisory basis, the executive compensation program, with about 68 million votes in favor and relatively few votes against or abstaining. In addition, they strongly ratified the Audit Committee’s selection of Ernst & Young LLP as independent registered public accounting firm for the year ending December 31, 2026. No other matters were brought to a vote.

Positive

  • None.

Negative

  • None.
Item 5.07 Submission of Matters to a Vote of Security Holders Governance
Results of a shareholder vote on proposals at an annual or special meeting.
Meeting date June 17, 2026 Date of annual meeting of stockholders
Votes for Bohen 67,474,365 votes Election of Sean Bohen as Class III director
Votes for Garland 66,184,382 votes Election of Scott Garland as Class III director
Votes for Larson 50,371,668 votes Election of Yi Larson as Class III director
Votes for Rappaport 67,276,575 votes Election of Andrew Rappaport as Class III director
Say-on-pay support 67,969,902 votes Advisory vote for executive compensation
Auditor ratification for 75,811,449 votes Ratification of Ernst & Young LLP for 2026
broker non-votes financial
"and the number of abstentions and broker non-votes with respect to each matter."
Broker non-votes occur when a brokerage firm is unable to vote on a shareholder’s behalf during a company election or decision because the shareholder has not given specific voting instructions, and the broker is not allowed or chooses not to vote on certain matters. They are important because they can affect the outcome of votes, especially when the results are close, by effectively reducing the total number of votes cast.
advisory basis financial
"The Company’s stockholders approved, on an advisory basis, the compensation awarded"
independent registered public accounting firm financial
"as the Company’s independent registered public accounting firm for the year ending December 31, 2026."
An independent registered public accounting firm is an outside accounting company officially registered with the government regulator to examine and report on a public company's financial records and controls. Investors treat its reports like an impartial inspector’s certificate — they add credibility to financial statements, help spot errors or misleading claims, and reduce the risk that shareholders are relying on unchecked or biased numbers.
Audit Committee financial
"the selection by the Audit Committee of the Company’s Board of Directors of Ernst & Young LLP"
A company's audit committee is a small group of board members who act like independent inspectors for the firm's finances, overseeing how financial reports are prepared, monitoring internal controls, and managing the relationship with external auditors. Investors care because a strong audit committee reduces the risk of accounting errors, fraud, or misleading statements, making financial statements more trustworthy and helping protect shareholder value.
definitive proxy statement regulatory
"in the Company’s definitive proxy statement filed with the Securities and Exchange Commission on April 29, 2026"
A Definitive Proxy Statement is a detailed document that a company sends to its shareholders before a big meeting, like voting on important decisions. It explains what's being voted on and gives important information so shareholders can make informed choices. It matters because it helps shareholders understand and participate in key company decisions.
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Understanding 8-K Material Events →
false000175028400017502842026-06-172026-06-17

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 17, 2026

 

 

Olema Pharmaceuticals, Inc.

(Exact name of Registrant as Specified in Its Charter)

 

 

Delaware

001-39712

30-0409740

(State or Other Jurisdiction
of Incorporation)

(Commission File Number)

(IRS Employer
Identification No.)

 

 

 

 

 

780 Brannan Street

 

San Francisco, California

 

94103

(Address of Principal Executive Offices)

 

(Zip Code)

 

Registrant’s Telephone Number, Including Area Code: 415 651-3316

 

N/A

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class

 

Trading
Symbol(s)

 


Name of each exchange on which registered

Common Stock, par value $0.0001 per share

 

OLMA

 

The Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

Item 5.07 Submission of Matters to a Vote of Security Holders.

On June 17, 2026, Olema Pharmaceuticals, Inc. (the “Company”) held its annual meeting of stockholders (the “Annual Meeting”). The following is a brief description of each matter voted upon at the Annual Meeting, as well as the number of votes cast for or against each matter and the number of abstentions and broker non-votes with respect to each matter. A more complete description of each matter can be found in the Company’s definitive proxy statement filed with the Securities and Exchange Commission on April 29, 2026 (the “Proxy Statement”). Voting results are, when applicable, reported by rounding fractional share voting down to the nearest whole number.

 

Proposal 1—Election of Directors

 

Final Voting Results

 

Nominees

 

For

 

Withheld

 

Broker Non-Votes

Sean Bohen, M.D., Ph.D.

 

67,474,365

 

1,165,382

 

7,496,139

Scott Garland

 

66,184,382

 

2,455,365

 

7,496,139

Yi Larson

 

50,371,668

 

18,268,079

 

7,496,139

Andrew Rappaport

 

67,276,575

 

1,363,172

 

7,496,139

 

The Company's stockholders elected each of the four nominees as Class III directors to hold office until the Company’s 2029 annual meeting of stockholders and until their respective successors have been duly elected and qualified.

 

Proposal 2—Advisory Vote on Executive Compensation

 

Final Voting Results

 

For

 

Against

 

Abstain

 

Broker Non-Votes

67,969,902

 

653,979

 

15,867

 

7,496,139

 

The Company’s stockholders approved, on an advisory basis, the compensation awarded to the Company’s named executive officers, as disclosed in the Proxy Statement.

 

Proposal 3—Ratification of Selection of Independent Registered Public Accounting Firm

 

Final Voting Results

 

For

 

Against

 

Abstain

75,811,449

 

271,918

 

52,520

 

The Company’s stockholders ratified the selection by the Audit Committee of the Company’s Board of Directors of Ernst & Young LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2026.

 

No other matters were submitted for stockholder action.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

 

OLEMA PHARMACEUTICALS, INC.

 

 

 

 

Date:

June 23, 2026

By:

/s/ Sean Bohen, M.D., Ph.D.

 

 

 

Sean Bohen, M.D., Ph.D.
President and Chief Financial Officer

 

Source: View Original Filing on SEC EDGAR

FAQ

What key decisions were made at Olema Pharmaceuticals (OLMA) 2026 annual meeting?

Stockholders elected four Class III directors through 2029, approved executive compensation on an advisory basis, and ratified Ernst & Young LLP as independent auditor for the year ending December 31, 2026, with no other matters submitted for action.

Which directors were elected at Olema Pharmaceuticals (OLMA) 2026 annual stockholder meeting?

Sean Bohen, Scott Garland, Yi Larson, and Andrew Rappaport were elected as Class III directors. They will serve until Olema’s 2029 annual meeting of stockholders and until their respective successors have been duly elected and qualified under the company’s governance structure.

How did Olema Pharmaceuticals (OLMA) stockholders vote on executive compensation in 2026?

Stockholders approved the company’s named executive officer compensation on an advisory basis, with 67,969,902 votes for, 653,979 against, and 15,867 abstentions, plus 7,496,139 broker non-votes. This supports the compensation program disclosed in the April 29, 2026 proxy statement.

Who is Olema Pharmaceuticals’ (OLMA) independent registered public accounting firm for 2026?

Stockholders ratified the Audit Committee’s selection of Ernst & Young LLP as Olema’s independent registered public accounting firm for the year ending December 31, 2026, with 75,811,449 votes for, 271,918 against, and 52,520 abstentions recorded in the voting results.

Were there any other matters voted on at Olema Pharmaceuticals (OLMA) 2026 annual meeting?

No. Beyond director elections, the advisory vote on executive compensation, and ratification of Ernst & Young LLP as auditor, no other matters were submitted for stockholder action at Olema Pharmaceuticals’ 2026 annual meeting, according to the disclosed voting results.

How strong was support for Olema Pharmaceuticals (OLMA) 2026 director nominees?

Support was high for most nominees. For example, Sean Bohen received 67,474,365 votes for and 1,165,382 withheld, with 7,496,139 broker non-votes. Similar strong majorities were recorded for Scott Garland and Andrew Rappaport, while Yi Larson received more withheld votes.

Filing Exhibits & Attachments

1 document

Other Documents